Table 5. Hazard ratios associated with a positive vs a negative BRCA2 mutation status, overall and according to ER status, and for women in different treatment categories (period of diagnosis 1980–2012).

	HR	95% CI	P-value
BRCA2	1.85a	1.35–2.52	<0.001
BRCA2 (multivariate)	1.61b	1.11–2.35	0.01
ER status
Positive	1.92b	1.20–3.05	0.006
Negative	1.12b	0.54–2.31	0.77
Surgery
Lumpectomy	4.16b	1.88–9.17	<0.001
Mastectomy	1.25b	0.82–1.93	0.3
Adjuvant chemotherapy
None	2.38b	1.31–4.34	0.005
Any	1.21b	0.74–2.00	0.45
Anthracycline	1.31b	0.58–2.95	0.52
Non-anthracycline	1.19b	0.61–2.27	0.62
Radiation
None	1.18b	0.68–2.06	0.55
Any	2.07b	1.23–3.50	0.006
Adjuvant hormone therapy
None	1.37b	0.85–2.21	0.2
Any	3.13b	1.53–6.41	0.002

Abbreviations: ER=oestrogen receptor; HR=hazard ratio.

^aAdjusted for year of birth and year of diagnosis.

^bAdjusted for year of birth, year of diagnosis, size, nodal status, grade, ER status and all other treatment categories.